Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA

References

• Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, US: Centers for Disease Control and Prevention, 2014. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html. Accessed July 14, 2016
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation; 2015
   Google Scholar
• Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014;370:1514-23
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care 2016;39:S52-S9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 5. Glycemic targets. Diabetes Care 2016;39:S39-S46
   PubMed Web of Science ®Google Scholar
• Langer J, Tian Y, Weng W, et al. Assessing unmet needs for type 2 diabetes patients treated with basal insulin in the United States. Endocrine Prac 2016;22(S2):78-9
   Google Scholar
• Gough SC, Jain R, Woo VC. Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2016;11:7-19
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:885-93
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:885-932
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014;37:2926-33
   PubMed Web of Science ®Google Scholar
• Linjawi S, Bode B, Chaykin L, et al. Efficacy and safety of IDegLira (combination of insulin degludec + liraglutide), in insulin-naïve patients with T2D uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy. Diabetes 2015;64(Suppl.1):A255. abstract 1002-P
   Web of Science ®Google Scholar
• Rodbard HW, Bode B, Harris S, et al. IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV study. Diabetes. 2015;64(Suppl.1):A255-A256. abstract 1003-P
   Web of Science ®Google Scholar
• Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 2016;315:898-907
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl1):5-26
   Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl1):27-40
   Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996
   Google Scholar
• Freemantle N, Mamdani M, Vilsbøll T, et al. IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther 2015;6:573-91
   PubMed Web of Science ®Google Scholar
• EUnetHTA. European Network for Health Technology. Guideline—comparators & comparisons: direct and indirect comparisons. Diemen: Netherlands, February 2013. http://5026.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Direct%20and%20indirect%20comparisons.pdf [Last accessed 14 July 2016]
   Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014;37:2926-33
   PubMed Web of Science ®Google Scholar
• Ahmann A, Rodbard HW, Rosenstock J, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015;17:1056-64
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
   PubMed Web of Science ®Google Scholar
• Yeaw J, Halinan S, Hines D, et al. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy 2014;12:219-30
   PubMedGoogle Scholar
• Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ 2015;18:420-32
   PubMed Web of Science ®Google Scholar
• Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol 2010;128:1335-40
   PubMedGoogle Scholar
• Department of Health and Human Services. Questionable billing by suppliers of lower limb prostheses. Washington, DC: Department of Health and Human Services, 2011. https://oig.hhs.gov/oei/reports/oei-02-10-00170.pdf [Last accessed 14 July 2016]
   Google Scholar
• Carroll K. Older adults can thrive as prosthesis users. Senior Step. Manassas, VA: National Limb Loss Information Center, 2004. http://www.amputee-coalition.org/senior_step/older_prosthesis_users.html [Last accessed 14 July 2016]
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009;52:1778-88
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
   PubMed Web of Science ®Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14:77-82
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making; 2011; last updated April 2012. http://www.nicedsu.org.uk/TSD1%20Introduction.final.08.05.12.pdf [Last accessed 14 July 2016]
   Google Scholar